好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Presence of Constipation in Amyotrophic Lateral Sclerosis and Correlation With Disease Characteristics
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (8:00 AM-9:00 AM)
9-017

To assess the prevalence of constipation in individuals with amyotrophic lateral sclerosis (ALS) and examine its relationship to disease features in a retrospective cohort at a single institution.

Constipation is a common concern among individuals with ALS, though its true prevalence and association with disease characteristics remain unclear.

ALS participants completing a new intake form were evaluated at their most recent clinic visit for the presence of constipation, disease duration, percutaneous endoscopic gastrostomy (PEG) placement, forced vital capacity (FVC), use of BiPAP, total, bulbar domain, and gross motor domain scores on the revised ALS Functional Rating Scale (ALSFRS-R), and King’s staging. Group comparisons were conducted using unpaired Student’s t-test and Chi-square tests.

Constipation was reported by 59.5% (22/37) of participants. Those reporting constipation had significantly lower ALSFRS-R total scores (22.4 vs. 29.9, p=0.015), lower bulbar domain scores (5.9 vs. 9.0, p=0.004), and more advanced King’s staging (3.9 vs. 3.1, p=0.004) compared to those without constipation. Gross motor domain scores trended lower among those with constipation but did not reach statistical significance (3.9 vs. 6.1, p=0.083). Participants with constipation also had a significantly lower FVC (51.2% vs. 74.3%, p=0.006) and were more likely to use BiPAP (81.0% vs. 46.7%, p=0.032). No significant differences were observed for disease duration (28.5 vs. 24.7 months, p=0.744) or PEG placement (25% vs. 20%, p=0.737).

Constipation was reported in the majority of ALS participants. It correlated with lower total ALSFRS-R scores, higher King’s staging, lower FVC, and use of BiPAP, consistent with greater disease burden but not with disease duration. Constipation also correlated with lower ALSFRS-R bulbar but not gross motor domain scores, suggesting that poor oral intake represents a risk factor for constipation, whereas decreased mobility plays a less certain role. PEG placement did not appear to influence constipation, though few participants utilized enteral nutrition.


Authors/Disclosures
Ipshita Tripathi, Student
PRESENTER
Ms. Tripathi has nothing to disclose.
WenPei Y. Ridenour, RN Ms. Ridenour has nothing to disclose.
Leo H. Wang, MD, PhD, FAAN (University of Washington) Dr. Wang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AskBio. Dr. Wang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Fulcrum Therapeutics. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Wang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Wang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Avidity. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Wang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sarepta. Dr. Wang has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. The institution of Dr. Wang has received research support from National Institute of Health. Dr. Wang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant with US Government.
Michael D. Weiss, MD, FAAN (University of Washington Medical Center, Department of Neurology) Dr. Weiss has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB-RA. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Soleo. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Weiss has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi.